Stifel Reiterates Hold Rating on Aclaris Therapeutis (ACRS)

Goldman Comments on Aclaris Therapeutics (ACRS), Shares up 33% Today, Up 245% Over Past 30 Days

Goldman Comments on Aclaris Therapeutics (NASDAQ: ACRS)

The analyst comments "This morning, ACRS announced it has entered into a license agreement with Biosion for global rights (excluding China) to BSI-045B (also known as TQC2731), an anti-TSLP monoclonal antibody (mAb), and BSI-502, an anti-TSLP plus anti-IL4R... More

Leerink Partners Upgrades Aclaris Therapeutis (ACRS) to Outperform, Shares +20% in Premarket Session

(Updated - November 19, 2024 7:19 AM EST)

Leerink Partners analyst Thomas J. Smith upgraded Aclaris Therapeutis (NASDAQ: ACRS) from Market Perform to Outperform with a price target of $7.00 (from $2.00).

The analyst comments "We are upgrading ACRS to Outperform (from Market Perform) and raising our PT... More

Piper Sandler Upgrades Aclaris Therapeutis (ACRS) to Overweight, PT $13

Piper Sandler analyst Christopher Raymond upgraded Aclaris Therapeutis (NASDAQ: ACRS) from Neutral to Overweight with a price target of $13.00 (from $3.00).

The analyst comments "Upgrading ACRS shares to Overweight after what we see as a transformative deal to acquire two novel I&I... More

Aclaris Therapeutics (ACRS) Announces 35.56M Share Offering at $2.25/sh

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of 35,555,555 shares of common stock at a purchase price of $2.25 per share, for gross proceeds of approximately $80.0 million. The private placement is expected to close on or about November 19, 2024, subject to the satisfaction of customary closing conditions.

The private placement... More

Aclaris Therapeutics (ACRS) Announces Exclusive, Global License Agreement with Biosion

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered into an exclusive license agreement with Biosion, Inc. (Biosion) for worldwide rights (excluding Greater China) to BSI-045B, a potential best-in-class, clinical-stage, novel anti-TSLP monoclonal antibody, and BSI-502, a potential best-in-class, pre-clinical stage, novel bispecific antibody that is directed against both TSLP and IL4R.

This transformative transaction, which marks the completion of our strategic review process, accelerates our evolution into becoming a leading immunology company with... More